Abstract: Disclosed are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.

Abstract: Provided herein are systems and methods for electrically stimulating cultured cells, including cardiomyocytes. In particular, provided herein are systems and methods employing reusable electrode arrays with multiwell culture devices that provide electrical stimulation to cells that are cultured in individual wells of the devices. The technologies described may be used to stimulate cells for phenotype analysis.

Abstract: Disclosed are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.

Abstract: Disclosed herein are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed herein is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed herein are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.

Abstract: Disclosed herein are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed herein is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed herein are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.

Abstract: The present disclosure provides compositions and methods employing stem cell-derived cardiomyocytes. In some embodiments, compositions for assessing cardiotoxicity using 3-dimensional cultures of stem-cell cardiomyocytes are provided.

Abstract: Provided herein are systems and methods for cardiomyocyte pacing of cultured cells, including cardiomyoctyes. In particular, provided herein are systems and methods employing electrode arrays with multiwell culture devices that provide electrical stimulation to cells cultured in individual wells of the devices.

Abstract: The present disclosure provides compositions and methods employing stem cell-derived cardiomyocytes. In some embodiments, methods of generating cardiomyocytes from stem cells (e.g., induced pluripotent stem cells (iPS cells or IPSCs) and embryonic stem cells) are provided. In some embodiments, uses of such cells for research, compound screening and analysis, and therapeutics are provided.